DRAFT 

ADVISORY BOARD ON RADIATION AND WORKER HEALTH 

NATIONAL INSTITUTE FOR 

OCCUPATIONAL SAFETY AND HEALTH 

A REVIEW OF NIOSH’S PROGRAM EVALUATION REPORT 

OCAS-PER-017, “EVALUATION OF INCOMPLETE INTERNAL 

DOSIMETRY RECORDS FROM IDAHO, ARGONNE – EAST 

AND ARGONNE – WEST NATIONAL LABORATORIES” 

Contract No. 200-2009-28555 

SCA-TR-PR2012-0017, Rev. 0 

Prepared by 

U. Hans Behling, PhD, MPH 

SC&A, Inc. 

S. Cohen & Associates 

1608 Spring Hill Road, Suite 400 

Vienna, VA 22182 

May 2012 

Disclaimer 

This document is made available in accordance with the unanimous desire of the Advisory Board on 

Radiation and Worker Health (ABRWH) to maintain all possible openness in its deliberations. However, 

the ABRWH and its contractor, SC&A, caution the reader that at the time of its release, this report is predecisional and has not been reviewed by the Board for factual accuracy or applicability within the 

requirements of 42 CFR 82. This implies that once reviewed by the ABRWH, the Board’s position may 

differ from the report’s conclusions. Thus, the reader should be cautioned that this report is for 

information only and that premature interpretations regarding its conclusions are unwarranted.

 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

2 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

Document No. 

SCA-TR-PR2012-0017 

S. COHEN & ASSOCIATES: 

Technical Support for the Advisory Board on

Radiation & Worker Health Review of 

NIOSH Dose Reconstruction Program 

Effective Date: 

Draft – May 15, 2012 

A Review of NIOSH’s Program Evaluation 

Report OCAS-PER-017, “Evaluation Of 

Incomplete Internal Dosimetry Records From 

Idaho, Argonne – East And Argonne – West 

National Laboratories” 

Page 2 of 49 

Task Manager/Reviewer: 

________________________ Date: ___________ 

U. Hans Behling, PhD, MPH 

Supersedes: 

N/A 

Project Manager: 

________________________ Date: ___________ 

John Stiver, CHP 

Reviewer(s): 

 John Mauro 

 John Stiver 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

3 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

TABLE OF CONTENTS 

 

1.0 Statement of Purpose ...........................................................................................................4 

2.0 Subtask 1: Identify the Circumstances that Necessitated OCAS-PER-017........................6 

3.0 Subtask 2: Assess NIOSH’s Approach and Methods for Corrective Action......................7 

4.0

................................................................................8 

Subtask 3: Evaluate the PER’s Stated Approach for Identifying the Number of 

DRs Requiring Re-evaluation of Dose

5.0 Subtask 4: Conduct Audits of a Sample-Set of DRs Affected by OCAS-PER-017...........9 

6.0 Summary Conclusions.......................................................................................................10 

7.0 References..........................................................................................................................11 

Appendix A: Review of INL Cases with POC <50% Potentially Affected by OCAS-PER017......................................................................................................................................12 

Appendix B: Review of ANL-W Cases with POC <50% Potentially Affected by OCASPER-017.............................................................................................................................39

Appendix C: Review of ANL-E Cases with POC <50% Potentially 

Affected by OCAS-PER-017.............................................................................................43 

Appendix D: INL Case Rework Status........................................................................................46 

Appendix E: ANL-W Case Rework Status..................................................................................48 

Appendix F: ANL-E Case Rework Status...................................................................................49 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

4 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

1.0 STATEMENT OF PURPOSE 

 

To support dose reconstruction (DR), the National Institute for Occupational Safety and Health 

(NIOSH) and the Oak Ridge Associated Universities Team (ORAUT) have assembled a large 

body of guidance documents, workbooks, computer codes, and tools. In recognition of the fact 

that all of these supporting elements in DR may be subject to revisions, provisions exist for 

evaluating the effect of such programmatic revisions on the outcome of previously completed 

DRs. Such revisions may be prompted by document revisions due to new information, 

misinterpretation of guidance, changes in policy, and/or programmatic improvements. 

The process for evaluating potential impacts of programmatic changes on previously completed 

DRs has been proceduralized in OCAS-PR-008, Preparation of Program Evaluation Reports 

and Program Evaluation Plans (OCAS 2006), Revision 2 dated December 6, 2006. This 

procedure describes the format and methodology to be employed in preparing a Program 

Evaluation Report (PER) and a Program Evaluation Plan (PEP). 

A PER provides a critical evaluation of the effect(s) that a given issue/programmatic change may 

have on previously completed DRs. This includes a qualitative and quantitative assessment of 

potential impacts. Most important in this assessment are the potential impacts on the Probability 

of Causation (POC) of previously completed DRs with POCs <50%. 

As needed, a PEP may be issued that serves as a formal notification of an impending PER. The 

PEP provides a preliminary description of the issue(s) that will be addressed in the PER, and 

summarizes the likely scope of the effort required to complete the PER. 

During an Advisory Board meeting on May 20, 2010, SC&A was tasked by the Advisory Board 

to conduct a review of OCAS-PER-017, Evaluation of Incomplete Internal Dosimetry Records 

from Idaho, Argonne – East and Argonne – West National Laboratories (OCAS 2007). In 

conducting a PER review, SC&A is committed to perform the following five subtasks, each of 

which is discussed in this report: 

Subtask 1: Assess NIOSH’s evaluation/characterization of the “issue” and its potential impacts 

on DR. Our assessment intends to ensure that the “issue” was fully understood and 

characterized in the PER. 

Subtask 2: Assess NIOSH’s specific methods for corrective action. In instances where the PER 

involves a technical issue that is supported by document(s) (e.g., white papers, technical 

information bulletins, procedures) that have not yet been subjected to a formal SC&A 

review, Subtask 2 will include a review of the scientific basis and/or sources of 

information to ensure the credibility of the corrective action and its consistency with 

current/consensus science. Conversely, if such technical documentation has been 

formalized and previously subjected to a review by SC&A, Subtask 2 will simply provide 

a brief summary/conclusion of this review process. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

5 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

Subtask 3: Evaluate the PER’s stated approach for identifying the universe of potentially 

affected DRs, and assess the criteria by which a subset of potentially affected DRs was 

selected for re-evaluation. The second step may have important implications in instances 

where the universe of DRs is too large and, for reasons of practicality, NIOSH’s reevaluation is confined to a subset of DRs. In behalf of Subtask 3, SC&A will also 

evaluate the timeliness for the completion of the PER. 

Subtask 4: Conduct audits of DRs affected by the PER under review. The number of DRs 

selected for audit for a given PER will vary. The selection of the DRs and the total 

number of DR audits per PER will be made by the Advisory Board. 

Subtask 5: Prepare a comprehensive written report that contains the results of the above-stated 

subtasks, along with our review conclusions. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

6 of 49

 This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

NOTICE:

2.0 SUBTASK 1: IDENTIFY THE CIRCUMSTANCES THAT 

NECESSITATED OCAS-PER-017 

In April/May 2006, two DR reviews involving claimants exposed at Idaho National Laboratory 

(INL) and Argonne National Laboratory-East (ANL-E), respectively, contained questionable 

notations in response to requests for internal monitoring data. For the INL claim, the notation 

stated, “no recordable dose,” and for the ANL-E claim, the notation stated, “no internal dose.” 

Further inquiries revealed that INL, ANL-E, and Argonne National Laboratory-West (ANL-W) 

did not consistently include internal dose data in response to requests for such data by NIOSH. 

NIOSH concluded that for a given energy employee (EE), INL, ANL-E, and ANL-W either 

provided all or none of the EE’s internal monitoring records. The potential for missed internal 

dosimetry data that had been requested but not received by NIOSH centered around handwritten 

notations in the OCAS-INT-004 (OCAS 2001) check-box form that either stated “no internal 

dose” or “no recordable dose.” 

SC&A’s Comments. NIOSH’s review of DRs and follow-up concerns regarding the notations of 

“no recordable dose” and “no internal dose” in the INL/ANL-E internal dosimetry responses is 

commendable. Further inquiries by NIOSH revealed instances where some EEs may have been 

monitored for internal exposure but request for such records had not been provided. NIOSH 

correctly concluded that in such instances, the corresponding reconstruction of organ dose(s) and 

derived POC were potentially incorrect. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

7 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

3.0 SUBTASK 2: ASSESS NIOSH’S APPROACH AND METHODS FOR 

CORRECTIVE ACTION 

With the realization in July/August 2006 that some EEs at INL, ANL-W, and ANL-E may have 

been monitored for internal exposure, but whose internal dosimetry records may not have been 

made available for DR, NIOSH pursued the following corrective steps in order to determine the 

universe (or maximum potential number) of claims that could have been impacted by incomplete 

internal dosimetry records. 

 Determined the total number of non-compensated claims. As of January 24, 2007, there 

were 677 INL, 87 ANL-W, and 69 ANL-E submitted/non-compensated claims, for a total 

of 833 claims. 

 Reviewed each case with respect to the completion of the internal dosimetry status 

section. 

 Based on information and notations contained in OCAS-INT-004, determined which of 

the 833 claims qualified for additional requests of internal monitoring data. 

SC&A’s Comments. At the time of SC&A’s review of OCAS-PER-017, SC&A requested 

NIOSH to provide information that would identify the 677 INL, 87 ANL-W, and 69 ANL-E 

claims, along with key information of the initial dose-record response used by NIOSH for further 

evaluation and selection of DRs, which required re-evaluation. 

In response to SC&A’s request, NIOSH identified potentially affected claims for each of the 

three facilities, along with initial responses to NIOSH’s request for internal dosimetry data. A 

cross-reference of the EEs’ ID numbers by NIOSH revealed that some claimants had been 

employed at more than one of the three sites; this reduced the total number of potentially affected 

claims from the earlier estimate of 833 to 789. Initial responses to requests for internal 

dosimetry data are summarized in Columns B and C of enclosed Appendices A, B, and C and 

were used by NIOSH to select those cases where additional information was sought. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

8 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

4.0 SUBTASK 3: EVALUATE THE PER’s STATED APPROACH FOR 

IDENTIFYING THE NUMBER OF DRs REQUIRING RE-EVALUATION 

OF DOSE 

Section 2.0 of PER-017 identified the following set of criteria for identifying those claims for 

which the initial request for internal dose data contained the following notations, which in turn 

mandated a request for additional internal dosimetry data. 

1. There were no internal dose records in the original response along with or without a 

handwritten note stating “no internal or recordable dose.” 

2. There were no internal dose records in the original response, and the OCAS-INT-004 was 

marked as “internal dosimetry records not readily available,” or without a handwritten 

note stating “no internal or recordable dose.” 

3. The OCAS-INT-004 contained no markings or notations and there were no internal dose 

records provided in the original response. (Note: Initial responses to requests for internal 

dosimetry data are summarized in Columns B and C of Appendices A, B, and C and were 

used by NIOSH to select those cases where additional information was requested.) 

Using these criteria, NIOSH identified a total of 223 cases from among 789 non-compensated 

claims for which further information and clarification of internal exposure were requested. 

Responses for 142 cases contained notes stating that the EE was either not monitored or that no 

internal exposure records/bioassay records could be found (see Columns D and E of Appendices 

A, B, and C). Additional requests for internal dose/bioassay data were therefore not generated 

for cases when this information was provided within the response, since NIOSH concluded that 

there was no need for the re-evaluation of dose. 

In total, NIOSH identified 83 cases for which responses dictated the need for a re-evaluation of 

EE doses with the following representation: 62 INL, 14 ANL-W, 6 ANL-E, and 1 with 

employment at both INL and ANL-W. 

SC&A’s Comments. SC&A reviewed data/information received from NIOSH (collated herein 

as Appendices A, B, and C) with the following objectives: 

1. Assess initial dosimetry responses summarized in Columns B and C of the Appendices in 

order to verify the number of cases for which additional data requests were sought 

2. Assess second responses summarized in Columns D and E in order to verify the number 

of cases for which a new DR is required 

Our review of the data found no inconsistencies/errors with the identification and selection of 

cases as specified in Section 2.0 of OCAS-PER-017. As a benefit to the reader, SC&A 

highlighted the 83 cases, as shown in Appendices A, B, and C. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

9 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

5.0 SUBTASK 4: CONDUCT AUDITS OF A SAMPLE-SET OF DRS 

AFFECTED BY OCAS-PER-017 

SC&A contacted NIOSH in order to determine the extent of completion of the 83 cases requiring 

a new DR. SC&A was told that those data were not readily available. 

By means of the claims’ ID numbers, SC&A independently assessed the current status of the 83 

cases in the NOCTS database. (Note: Claim ID numbers are not identified in Appendices A, B, 

and C.) The current status for the 83 cases is shown in Appendices D, E, and F for INL, 

ANL-W, and ANL-E, respectively. For illustration, Appendix D identifies the status of 63 INL 

cases: (1) 38 cases have a completed revised DR that has been adjudicated by the DOL; (2) 12 

cases have a completed revised DR, but without a final DOL decision; and (3) 13 cases are still 

awaiting completion of a revised DR. 

Selection of DRs for SC&A’s audit by the Dose Reconstruction Subcommittee will be limited to 

completed DRs that have been adjudicated by the DOL. Pending approval by the Subcommittee, 

SC&A recommends selection of at least 3 INL cases, 2 ANL-W cases, and 1 ANL-E case. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

10 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

6.0 SUMMARY CONCLUSIONS 

In behalf of the four subtasks evaluated under OCAS-PER-017, SC&A identified no findings and 

is in agreement with the corrective actions taken by NIOSH. 

Given the fact that SC&A has not identified findings regarding OCAS-PER-017, it may be 

prudent to not delay selection of auditable cases as defined in Section 5.0 (Subtask 4) above. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

11 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

7.0 REFERENCES 

OCAS 2001. Request for Personnel Exposure Information Under the Energy Employees 

Occupational Illness Compensation Program Act, OCAS-INT-004, Revision 0, NIOSH’s Office 

of Compensation Analysis and Support, Cincinnati, Ohio. November 20, 2001.

OCAS 2006. Preparation of Program Evaluation Reports and Program Evaluation Plans, 

OCAS-PR-008, Revision 2, NIOSH’s Office of Compensation Analysis and Support, 

Cincinnati, Ohio. December 6, 2006. 

OCAS 2007. Evaluation of Incomplete Internal Dosimetry Records from Idaho, Argonne – East 

and Argonne – West National Laboratories, OCAS-PER-017, Revision 00, NIOSH’s Office of 

Compensation Analysis and Support, Cincinnati, Ohio. September 11, 2007. 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

12 of 49

APPENDIX A: REVIEW OF INL CASES WITH POC <50% 

POTENTIALLY AFFECTED BY OCAS-PER-017 

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

1 marked as not readily available; no hand- written note in-vivo summary (90)/in-vivo (90) provided 2 marked as provided; note: no internal 

exposure 

in-vivo summary (66, 83–85, 89–91)/in-vivo (66, 69, 83–85, 89–91)/bioassay (62–66) provided 

3 marked as not readily available; no hand- written note in-vivo summary (66, 85)/in-vivo (66, 85)/bioassay (56–57, 59, 61–65) provided 4 marked as not readily available; no hand- written note in-vivo summary (78–80)/in-vivo (77–80) provided 5 marked as provided; no hand-written note marked as provided; note: see transmittal letter no

bi

6 marked as provided; note: no internal dose in-vivo summary (66, 69, 81–85)/in-vivo (73, 76, 81– 85) provided 7 marked as provided; no hand-written note in-vivo (91) provided 8 marked as provided; no hand-written note in-vivo (61–62, 65–66, 81)/bioassay (56–58, 60–65) provided 9 marked as provided; no hand-written note in-vivo (68, 71–73, 78, 82, 84–87, 89–94)/bioassay (68) provided 

10 no notations/markings in-vivo summary (65–66, 82, 92)/in-vivo (63–66, 69, 82, 92)/bioassay (55–65) provided 11 marked as provided; note: no internal dose in-vivo summary (81–84, 87, 93–94)/in-vivo (81–84, 87, 93–94) provided 12 marked as provided; note: no internal dose bioassay (61–64) provided 13 marked as provided; note: no internal dose in-vivo (90) provided 14 

marked as provided; note: no internal dose/no recordable dose 

in-vivo summary (80, 82–86, 89–92)/in-vivo (62–63, 71, 73, 80, 82–86, 89–92)/bioassay (56–65, 67) provided 

15 marked as provided; no hand-written note in-vivo summary (65–66, 80–85)/in-vivo (63–66, 70, 72, 76, 81–85)/bioassay (56–66) provided 16 marked as provided; note: no internal dose in-vivo summary (65, 80)/in-vivo (65, 80)/bioassay (62–65) provided 17 marked as provided; note: no internal exposure – no wbc marked as does not exist; note: see attached letter no

bi

18 

marked as provided; note: no internal exposure; note in second response: no recordable dose 

in-vivo (63–64, 66, 68, 72, 74, 76, 82, 86)/bioassay (55, 57–58, 61–65) provided 

19 marked as not readily available; no hand- written note in-vivo summary (84, 86–87, 89–91)/in-vivo (84, 86– 87, 89–91) provided 20 marked as provided; note: no internal dose in-vivo summary (81–82, 85, 90–92, 95)/in-vivo (81– 82, 85, 90–92, 95) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

13 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

21 marked as provided; note: no internal dose in-vivo summary (78–81, 83–93)/in-vivo (78–81, 83– 93)/bioassay (83–93) provided 22 marked as provided; no hand-written note in-vivo (74, 76–79, 81–90) provided 23 marked as provided; no hand-written note marked as provided; note: no recordable dose, see attached letter no

bi

24 marked as provided; no hand-written note in-vivo summary (80–93)/in-vivo (80–91, 93)/bioassay (88–91, 93) provided 25 marked as provided; note: no internal dose bioassay (53–57) provided 26 marked as provided; note: see attached in-vivo summary (78, 80)/in-vivo (61, 64, 69, 73–75, 77–78, 80)/bioassay (54–65)/thyroid (58) provided 27 marked as provided; note: no recordable dose bioassay (60) provided 28 marked as provided; no hand-written note in-vivo (66, 69, 72–73, 82–83, 85) provided 29 marked as provided; note: no recordable internal dose/no monitoring required 30 marked as provided; no hand-written note marked as provided; note: no recordable dose, see transmittal letter no

bi

31 marked as provided; note: no monitoring required in-vivo (86, 88–92) provided 32 marked as provided; no hand-written note marked as provided; note: see transmittal letter no

bi

33 marked as provided; note: no recordable internal dose/no monitoring required 34 marked as not readily available; no hand- written note in-vivo summary (80, 84–91)/in-vivo (80, 84–91) provided 35 marked as provided; note: no internal dose in-vivo summary (85, 93)/in-vivo (85, 93) provided 36 marked as provided; no hand-written note marked as provided; note: no recordable dose, see attached letter in

pr

37 marked as provided; note: no monitoring required 38 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter no

bi

39 marked as provided; note: no internal dose in-vivo summary (70)/in-vivo (70)/bioassay (62–65) provided 40 marked as provided; note: no internal dose in-vivo summary (79, 83, 95)/in-vivo (79, 83, 95)/bioassay (60–61) provided 41 marked as not readily available; no hand- written note in-vivo summary (82–88, 92–93)/in-vivo (82–88, 92– 93)/bioassay (82–83) provided 42 marked as provided; note: no internal dose in-vivo summary (83, 90–93)/in-vivo (83, 90–93) provided 43 marked as provided; note: no internal dose in-vivo (61, 63–64)/bioassay (56–64) provided 44 marked as provided; no hand-written note in-vivo summary (66, 83)/in-vivo (66, 69, 73, 77, 83)/bioassay (59–64) provided 45 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter no

bi

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

14 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

46 marked as provided; note: no internal dose – all dose from ANL in-vivo (65–66, 68–74, 76)/bioassay (61–66) provided 47 marked as provided; note: monitoring not required in-vivo (81, 83–95) provided 48 marked as not readily available; no hand- written note in-vivo summary (95)/in-vivo (95) provided 49 marked as provided; no hand-written note in-vivo summary (66, 70, 92)/in-vivo (63, 65–66, 70, 92)/bioassay (56–66) provided 50 marked as provided; note: no internal exposure – wbc dates in-vivo summary (82, 84–85, 90–92, 95–96)/in-vivo (82, 84–85, 90–92, 95) provided 51 marked as not readily available; no hand- written note in-vivo summary (82, 85)/in-vivo (82, 85) provided 52 marked as provided; no hand-written note in-vivo summary (91)/in-vivo (91) provided 53 marked as provided; note: no internal dose in-vivo summary (70)/in-vivo (64, 70, 73)/bioassay (57–59, 61–66) provided 54 marked as provided; note: no internal dose in-vivo (76–77) provided 55 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter in

pr

56 marked as provided; note: no internal 

exposure 

in-vivo summary (65, 70, 81)/in-vivo (62, 65, 69–70, 72, 78, 81)/bioassay (57–65) provided 

57 marked as provided; note: no internal dose bioassay (53–55, 57–58, 61–65, 69) provided 58 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter in

pr

59 marked as provided; no hand-written note in-vivo (68, 81, 92, 95)/bioassay (68) provided 60 note: not monitored notation in file that records show no record of EE being monitored or receiving dose at INL 61 marked as provided; note: no internal dose in-vivo (63, 69, 71)/bioassay (56–63) provided 62 marked as provided; note: no internal dose in-vivo summary (67, 70, 74, 76, 80, 83)/in-vivo (67, 70, 74, 76, 80, 83) provided 63 marked as provided; note: no internal dose in-vivo summary (65–66, 68, 85–86)/in-vivo (65–66, 68, 73, 85–86)/bioassay (56–61, 63–64, 68) provided 64 

marked as provided; no hand-written note in-vivo summary (79, 82–84, 86, 88, 90, 92, 94)/in-vivo 

(73, 79, 82–84, 86, 88, 90, 92, 94)/bioassay (61–63, 65–67) provided 

65 marked as provided; note: no monitoring required 66 marked as provided; no hand-written note in-vivo (90–91) provided 67 marked as provided; no hand-written note bioassay (59, 61–64) provided 68 marked as provided; note: no internal 

exposure 

in-vivo summary (78–79, 84)/in-vivo (77–78, 84) provided 

69 marked as provided; no hand-written note in-vivo summary (75)/in-vivo (62, 75)/bioassay (59–63) provided 70 marked as not readily available; no hand- written note marked as provided; note: no recordable dose no

bi

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

15 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

71 marked as provided; note: no internal dose in-vivo summary (81–82)/in-vivo (73–74, 81–82) provided 72 marked as provided; note: no internal dose in-vivo summary (82–84, 89–91, 94)/in-vivo (82–85, 89–91, 94) provided 73 marked as provided; note: no internal dose/no hand-written note bioassay (53) provided 74 marked as provided; note: no internal dose in-vivo summary (66, 70, 80, 82–87)/in-vivo (66, 70, 80, 82–87) provided 75 marked as provided; no hand-written note in-vivo summary (66, 83)/bioassay (63) provided 76 marked as provided; no hand-written note in-vivo summary (72)/in-vivo (72)/bioassay (55–56, 59, 61–64) provided 77 marked as provided; note: no internal dose bioassay (60–61, 65, 70) provided 78 marked as provided; no hand-written note in-vivo summary (66–67, 75)/in-vivo (63, 66–67, 75)/bioassay (62–64, 66) provided 79 

marked as provided; note: no internal dose/no recordable dose 

in-vivo summary (71, 75, 81–87, 90–92, 94–95)/in-vivo (63, 71, 74–75, 81–87, 90–92, 94–95)/bioassay (58–64, 68) provided 

80 marked as provided; note: no monitoring required 81 marked as not readily available; no hand- written note in-vivo summary (82–90)/in-vivo (82–90)/bioassay (83–86) provided 82 marked as provided; note: no monitoring required 83 marked as provided; note: no monitoring required 84 marked as provided; note: no monitoring required in-vivo (85) provided 85 marked as provided; note: no internal dose in-vivo summary (81, 89–90, 93, 95–96)/in-vivo (73, 77, 81, 89–90, 93, 95)/bioassay (68) provided 86 marked as provided; no hand-written note in-vivo (84, 86)/bioassay (55, 68) provided 87 marked as provided; no hand-written note in-vivo summary (70)/bioassay (64) provided 88 marked as not readily available; no hand- written note in-vivo (64–65)/bioassay (57, 60–62, 64–65) provided 89 marked as provided; note: no internal dose in-vivo summary (70, 82, 84, 86)/in-vivo (63–64, 70, 82, 84, 86)/bioassay (58–62, 64) provided 90 marked as provided; note: no internal dose in-vivo (74, 79, 82–87, 89, 91, 95) provided 91 marked as provided; note: no internal dose – wbc dates attached in-vivo summary (78)/in-vivo (78) provided 92 marked as provided; note: no internal exposure – wbc attached in-vivo summary (85)/in-vivo (85) provided 93 marked as provided; no hand-written note bioassay (59–60, 62–64) provided 94 marked as provided; note: no internal dose in-vivo summary (70, 82–83)/in-vivo (65, 70, 72, 74, 82–83)/bioassay (56, 58, 60, 62–65) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

16 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

95 

marked as provided; note: no internal dose in-vivo summary (70, 80, 82–83, 88–91, 94–95)/in-vivo 

(70, 74, 76, 80, 82–83, 88–91, 93–95)/bioassay (77–83) provided 

96 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

97 marked as not readily available; no hand- written note in-vivo (86–88, 90–91) provided 98 marked as provided; no hand-written note in-vivo (66–69, 75, 77–80)/bioassay (66–69) provided 99 marked as provided; note: no recordable internal dose marked as does not exist; note: see attached letter no

bi

100 marked as provided; note: no internal 

exposure 

in-vivo (73) provided 

101 marked as provided; note: no internal dose in-vivo (61)/bioassay (55–56, 60–62, 64–65) provided 102 marked as provided; note: no internal dose in-vivo (73–77, 81–84)/bioassay (75) provided 103 marked as provided; no hand-written note in-vivo (61)/bioassay (62, 64) provided 104 marked as provided; note: no internal dose in-vivo (89, 90)/bioassay (57–64) provided 105 marked as provided; note: no internal dose – wbc attached in-vivo summary (78–79)/in-vivo (78–79) provided 106 marked as provided; note: no internal dose – wbc dates provided/no recordable dose in-vivo (78–95) provided 107 all records marked does not exist 108 marked as provided; note: no internal exposure/no recordable dose in-vivo summary (65–66, 68, 76, 80–83)/in-vivo (63– 66, 68, 72, 76, 80–83)/bioassay (57–66, 68) provided 109 marked as provided; note: no internal dose – wbc dates attached in-vivo summary (82, 90)/in-vivo (82, 90) provided 110 marked as provided; note: no internal dose bioassay (55, 58, 62, 64) provided 111 marked as provided; note: no internal 

exposure 

in-vivo summary (84–92)/in-vivo (84–92) provided 

112 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see transmittal letter no

bi

113 no notations/markings in-vivo (73, 75–77, 79, 82–93, 95)/bioassay (57–63, 66) provided 114 marked as provided; note: no recordable internal dose/no monitoring required 115 marked as provided; note: no internal dose in-vivo summary (79–80, 84, 86–87)/in-vivo (80, 84, 86–87) provided 116 marked as provided; note: internal dose included/recordable dose included in-vivo summary (76, 78–98)/in-vivo (75–77, 79– 96)/bioassay (74, 81, 83–98) provided 117 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

118 marked as provided; note: no internal dose in-vivo summary (68–69, 78–80)/in-vivo (63, 65, 68, 78–80)/bioassay (63–65) provided 119 marked as provided; note: no internal dose in-vivo summary (80)/in-vivo (61–62, 80)/bioassay (60, 62–63) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

17 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

120 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter no

bi

121 marked as provided; note: no internal dose in-vivo (82–84)/bioassay (55–56, 61, 68) provided 122 marked as provided; no hand-written note in-vivo (66–67, 85–86)/bioassay (53–57, 60–64) provided 123 marked as provided; no hand-written note in-vivo (92) provided 124 marked as provided; note: no internal dose in-vivo (89–95) provided 125 marked as provided; note: no internal dose in-vivo summary (76, 79–80)/in-vivo (76, 80) provided 126 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

127 marked as provided; note: no internal dose in-vivo summary (77–79)/in-vivo (74–75) provided 128 marked as provided; note: no internal exposure – no wbc marked as does not exist; note: see attached letter no

bi

129 marked as provided; note: no internal dose in-vivo (70) provided 130 marked as not readily available; no hand- written note in-vivo summary (88–90, 92)/in-vivo (88–90, 92)/bioassay (88–96) provided 131 marked as provided; note: no internal dose – all NRF dose notation in file that all records are for NRF 132 marked as provided; no hand-written note in-vivo (66–67, 71, 73, 75, 77, 80, 82–92, 94– 95)/bioassay (65) provided 133 marked as provided; no hand-written note bioassay (58, 64) provided 134 marked as provided; note: no internal dose in-vivo (64–65, 69, 72, 76)/bioassay (53–55, 57–65, 78– 79) provided 135 all records marked dose not exist 136 marked as provided; no hand-written note in-vivo (64, 70)/bioassay (53–66) provided 137 marked as provided; note: no internal dose marked as provided; no hand-written note bi138 marked as provided; note: no internal dose in-vivo (84) provided 139 marked as provided; note: no internal dose in-vivo summary (65)/bioassay (59, 61–65) provided 140 marked as provided; note: no internal dose marked as provided; no hand-written note bi141 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

142 marked as provided; note: no internal dose in-vivo (75–76, 78–88) provided 143 marked as provided; no hand-written note in-vivo (85–86, 88)/bioassay (55, 57, 60–61, 64, 66) provided 144 marked as provided; no hand-written note in-vivo (62–63)/bioassay (53–63) provided 145 no notations/markings in-vivo (65)/bioassay (53–58) provided 146 marked as provided; note: no internal exposure – no wbc marked as does not exist; note: see attached letter no

bi

147 marked as provided; no hand-written note in-vivo (77)/bioassay (62, 64–65) provided 148 marked as provided; note: no internal dose in-vivo (94)/bioassay (57–61) provided 149 marked as provided; note: no recordable dose in-vivo summary (86–87)/in-vivo (86–87) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

18 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

150 marked as provided; no hand-written note in-vivo (68, 71–73, 76–77, 79, 82, 85–87, 93, 95)/bioassay (55–65) provided 151 marked as provided; note: no internal dose – no wbc marked as provided; no hand-written note bi

pr

152 marked as provided; note: no internal dose in-vivo summary (65, 81–87)/in-vivo (76, 81–87) provided 153 marked as provided; note: no internal marked as does not exist; note: see attached letter no

bi

154 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

155 marked as provided; note: no internal dose in-vivo (71)/bioassay (64) provided 156 marked as provided; no hand-written note in-vivo summary (84, 86–87, 90–92, 94–97)/in-vivo (84, 86–87, 90–92, 94–96) provided 157 marked as provided; no hand-written note in-vivo (66, 73, 79, 82–87, 89–90, 92–94)/bioassay (67) provided 158 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see transmittal letter no

bi

159 marked as provided; no hand-written note in-vivo (87, 92)/bioassay (53–60) provided 160 marked as provided; note: no internal 

exposure 

in-vivo summary (80, 82, 84, 88)/in-vivo (80–82, 84, 88) provided 

161 marked as provided; note: no internal dose in-vivo (62–66, 73, 85)/bioassay (54–65) provided 162 no notations/markings in-vivo (66–67)/bioassay (56–61, 65–67) provided 163 marked as provided; note: no internal dose in-vivo summary (69) provided 164 marked as provided; no hand-written note in-vivo (77, 82–89, 91–92)/bioassay (66) provided 165 marked as provided; note: no internal dose – wbc attached in-vivo summary (66, 91–95)/in-vivo (91–95) provided 166 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter no

bi

167 marked as provided; no hand-written note bioassay (56, 61–65) provided 168 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

169 marked as provided; note: no monitoring required 170 marked as provided; note: no internal dose – wbc attached in-vivo summary (80)/in-vivo (80) provided 171 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

172 marked as provided; note: no internal dose – all wbc for NRF marked as does not exist; note: see attached letter no

bi

173 marked as provided; note: no internal dose in-vivo summary (73)/in-vivo (73) provided 174 marked as provided; note: no internal dose – wbc attached in-vivo summary (81, 86–91, 96)/in-vivo (81, 86–91) provided 175 marked as provided; note: no internal 

exposure 

in-vivo summary (65–66, 78–81, 83–89, 91–94)/in-vivo (73–74, 77, 79–81, 83–89, 91–94) provided 

176 marked as provided; no hand-written note in-vivo (63–65, 69)/bioassay (53–56, 58–66) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

19 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

177 note: only has NRF dose notation in file that all records are for NRF; in-vivo (86, 89–90) provided 178 marked as provided; note: no internal dose – dates of wbc attached in-vivo summary (83–85) provided 179 marked as provided; note: no internal dose in-vivo (82, 85–86, 88–95) provided 180 marked as provided; note: no internal dose in-vivo (86, 95) provided 181 marked as provided; no hand-written note in-vivo (80–81)/bioassay (57–59, 61–63) provided 182 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter bi183 marked as provided; note: see attached in-vivo summary (90)/in-vivo (90) provided 184 marked as provided; note: no internal dose in-vivo summary (74)/in-vivo (68, 74)/bioassay (68) provided 185 marked as provided; note: no recordable dose in-vivo summary (66, 68, 82–83, 90)/in-vivo (73, 82– 83, 90) provided 186 note: NRF not reported notation in file that all records are for NRF; in-vivo (81) provided 187 marked as provided; note: no recordable dose in-vivo summary (83–85, 88–89, 91, 95)/in-vivo (83– 85, 88–89, 91, 95) provided 188 marked as not readily available; no hand- written note marked as provided; note: no recordable dose, see attached letter no

bi

189 marked as not readily available; no hand- written note in-vivo summary (85, 88–89, 92)/in-vivo (85, 88–89, 92) provided 190 marked as provided; no hand-written note in-vivo (68, 72, 74, 77)/bioassay (53–54, 56–66) provided 191 marked as provided; note: no internal 

exposure 

marked as does not exist; note: see 

attached letter 

nobi

192 all records marked does not exist notation in file that records show no record of EE receiving dose at INL 193 note: NRF not reported notation in file that all records are for NRF 194 marked as provided; note: no counts marked as does not exist; note: see attached letter no

bi

195 marked as provided; no hand-written note in-vivo (80)/bioassay (54, 57–58, 60–61) provided 196 marked as provided; note: no internal dose/no recordable dose in-vivo summary (66, 70, 72, 79, 81–86)/in-vivo (62, 65–66, 70)/bioassay (56–66) provided 197 marked as provided; note: no monitoring required 198 marked as provided; note: no internal dose – wbc attached in-vivo summary (82, 91–92)/in-vivo (82, 91–92) provided 199 marked as provided; no hand-written note in-vivo (80)/bioassay (60, 80) provided 200 marked as provided; note: no monitoring required in-vivo summary (91)/in-vivo (91) provided 201 marked as provided; note: wbc dates in-vivo summary (93)/in-vivo (93) provided 202 no notation; marked as not readily available in-vivo (66)/bioassay (55–56, 58–65) provided 203 marked as provided; note: no recordable internal dose marked as provided; no hand-written note bi

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

20 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

204 marked as provided; note: no internal dose in-vivo summary (81–85, 87–88)/in-vivo (81–85, 87– 88) provided 205 marked as provided; note: no recordable dose in-vivo summary (66, 73, 79)/in-vivo (66, 70, 73)/bioassay (57–66) provided 206 marked as provided; note: no internal dose in-vivo summary (75–76, 93)/in-vivo (93) provided 207 marked as provided; no hand-written note marked as provided; note: no recordable dose, see attached letter no

bi

208 marked as provided; note: no recordable dose in-vivo summary (87–88) provided 209 marked as does not exist; note: EE only worked one day/monitored for one day 210 

marked as provided; note: no recordable dose 

in-vivo summary (66, 78, 80)/in-vivo (63–66, 70, 72, 74–75, 77–78, 80)/bioassay (54–55, 57, 61–64, 66) provided 

211 marked as provided; note: no recordable dose bioassay (64) provided 212 marked as provided; note: no internal dose in-vivo summary (78, 82–88, 90, 92)/in-vivo (82–84, 86–88, 90, 92) provided 213 marked as provided; no hand-written note in-vivo (71)/bioassay (57–64) provided 214 marked as provided; no hand-written note bioassay (56–57, 59–61, 63–64, 68–69) provided 215 marked as provided; note: no internal dose – no wbc marked as provided; note: attached shows none were taken no

bi

216 no notations/markings marked as provided; note: no recordable dose, see attached letter no

bi

217 marked as provided; note: no internal dose – no wbc marked as does not exist; note: see attached letter no

bi

218 marked as provided; note: no monitoring required 219 marked as provided; note: internal dose results included in-vivo summary (78–81, 83–95)/in-vivo (78, 80–81, 84–95)/bioassay (81–95) provided 220 

marked as provided; no hand-written note; note in add response: no recordable dose 

in-vivo summary (66, 78–83, 85–88)/in-vivo (63, 66, 68, 75, 77–78, 80–83, 85–89)/bioassay (54–66) provided 

221 marked as provided; no hand-written note in-vivo (61, 73, 77, 86–87)/bioassay (55–59, 61) provided; thyroid count (58) 222 marked as provided; note: no internal dose in-vivo (73–74,76)/bioassay (63) provided 223 marked as provided; no hand-written note in-vivo (85)/bioassay (61–65) provided 224 marked as provided; note: no internal dose – no wbc marked as does not exist; note: see attached letter no

bi

225 all records marked does not exist notation in file that records show no record of EE receiving dose at INL 226 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

227 marked as provided; note: no internal dose in-vivo (63)/bioassay (57–65) provided 228 marked as provided; note: no internal dose bioassay (58, 65) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

21 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

229 marked as provided; note: no internal dose in-vivo summary (79, 82–85, 87, 90–91, 93–94)/in-vivo (79, 82–83, 85, 87, 90–91, 93–94) provided 230 marked as provided; no hand-written note in-vivo (66, 69, 73, 75, 77–78, 82–86)/bioassay (64–65) provided 231 marked as provided; no hand-written note bioassay (58–59) provided 232 all records marked does not exist notation in file that records show no record of EE receiving dose at INL 233 marked as provided; no hand-written note bioassay (57, 60, 65) provided 234 marked as provided; no hand-written note in-vivo (69, 73, 78, 81)/bioassay (57–59, 61–65) provided 235 marked as provided; no hand-written note in-vivo (73, 75–76, 79–85, 87, 90–91, 93) provided 236 marked as provided; note: no internal dose in-vivo summary (81, 85–90)/in-vivo (81, 85–90) provided 237 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter bi238 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

239 

marked as provided; note: no internal dose – wbc attached/no recordable dose – wbc attached 

in-vivo summary (77–92, 94–98)/in-vivo (78–92, 94–95)/bioassay (81, 83–96, 98) provided 

240 marked as provided; note: no internal dose in-vivo summary (84–86, 88–91, 93–94)/in-vivo (85– 86, 88–91, 93–94) provided 241 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

242 marked as provided; note: no internal records in-vivo (95) provided 243 marked as provided; note: no internal dose in-vivo (66–67)/bioassay (58–65) provided 244 marked as provided; note: no internal dose – no wbc marked as does not exist; note: no recordable dose, see attached letter no

bi

245 marked as provided; note: no internal dose in-vivo (82) provided 246 marked as provided; note: no internal dose in-vivo summary (92)/in-vivo (92) provided 247 marked as provided; note: no internal dose in-vivo (65–66, 70, 75–76, 81)/bioassay (61–66, 68) provided 248 marked as provided; no hand-written note in-vivo (63–64, 66–67, 71, 77, 80)/bioassay (60–66) provided 249 marked as provided; note: no internal dose in-vivo (68, 70, 77, 83)/bioassay (54–55, 57, 61–65) provided 250 note: NRF not reported notation in file that all records are NRF; in-vivo (86) provided 251 marked as provided; note: no internal dose – no wbc marked as does not exist; note: no recordable dose, see attached letter no

bi

252 marked as provided; note: no internal injury marked as does not exist; note: no recordable dose, see attached letter no

bi

253 no notations/markings in-vivo (65)/bioassay (61–65) provided 254 all records marked dose not exist 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

22 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

255 marked as provided; note: no internal records in-vivo (63–66, 68, 82, 89)/bioassay (56–66) provided 256 marked as provided; note: no internal dose in-vivo summary (75, 84, 87, 89, 91, 93–94, 97)/in-vivo (84, 87, 89, 91, 93–94) provided 257 marked as provided; note: no internal dose/no recordable dose in-vivo summary (90, 92–96)/in-vivo (90, 92–95) provided 258 marked as provided; note: no internal dose in-vivo (84–85, 87–88, 93) provided 259 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter bi260 marked as provided; note: no internal dose – no wbc marked as does not exist; note: no recordable dose, see attached letter no

bi

261 note: not reported – only ANL & NRF notation in file that all records are NRF or ANL 262 marked as provided; note: no internal dose in-vivo summary (70, 86)/in-vivo (70, 86)/bioassay (60, 62–63, 65) provided 263 marked as provided; note: no internal dose in-vivo (62, 66)/bioassay (59–60, 62–64, 66) provided 264 marked as provided; no hand-written note in-vivo (62, 65–67, 69, 77, 83, 86, 89, 91, 94)/bioassay (60–62, 70) provided 265 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

266 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter bi267 marked as provided; note: no internal 

exposure 

marked as does not exist; note: no 

recordable dose, see attached letter 

nobi

268 marked as provided; note: no monitoring required in-vivo (89–90) provided 269 marked as provided; note: no internal dose/no recordable dose in-vivo summary (70–71, 77–84)/in-vivo (70–71, 77, 80–84) provided 270 marked as provided; note: no internal dose in-vivo (87) provided 271 marked as provided; no hand-written note in-vivo (61, 65–66)/bioassay (57–66) provided 272 marked as provided; note: no internal dose in-vivo (63, 66, 68–69, 86)/bioassay (56–65, 69) provided 273 marked as provided; note: no internal dose in-vivo summary (85–92)/in-vivo (85–92) provided 274 marked as provided; note: no internal dose in-vivo (64–65, 71, 73)/bioassay (53–66) provided 275 marked as provided; note: no internal dose in-vivo summary (80, 82–85)/in-vivo (80, 82–85) provided 276 marked as provided; note: no internal in-vivo (63–67, 70, 78, 82–83, 85–87, 92, 94– 95)/bioassay (57–66) provided 277 marked as provided; note: no internal dose in-vivo (81, 86)/bioassay (56, 60–65) provided 278 marked as provided; no hand-written note bioassay (57–63, 66) provided 279 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

280 marked as provided; note: no internal dose in-vivo (84–85, 87–90) provided 281 marked as provided; note: no internal records in-vivo (85)/bioassay (53–58) provided 282 marked as provided; no hand-written note in-vivo summary (88)/in-vivo (88) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

23 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

283 note: not in our systems notation in file that records show no record of EE receiving dose at INL 284 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter bi285 marked as provided; no hand-written note in-vivo (67–68)/bioassay (68) provided 286 marked as provided; note: no internal dose in-vivo (78, 85)/bioassay (58, 60–61) provided 287 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

288 all records marked does not exist notation in file that records show no record of EE receiving dose at INL 289 marked as provided; no hand-written note bioassay (55, 57) provided 290 marked as provided; note: no analytical records in-vivo (63–66, 68, 70, 72)/bioassay (58–66, 68) provided 291 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

292 marked as provided; no hand-written note bioassay (56, 59–60, 62–64, 69) provided 293 marked as provided; no hand-written note bioassay (53) provided 294 marked as provided; no hand-written note bioassay (55, 58, 60–61, 63) provided 295 marked as provided; note: no internal in-vivo (80, 90) provided 296 marked as provided; note: no recordable dose note: no recordable dose, see attached letter no

bi

297 marked as provided; no hand-written note bioassay (54, 56–58, 60, 64) provided 298 marked as provided; no hand-written note bioassay (58, 61, 63–65) provided 299 marked as provided; no hand-written note in-vivo summary (67, 91)/in-vivo (67, 91) provided 300 marked as provided; note: no internal dose bioassay (55) provided 301 marked as provided; note: no internal 

exposure 

in-vivo summary (81–82, 90, 95)/in-vivo (81–82, 90, 95) provided 

302 marked as provided; no hand-written note bioassay (60–62, 64) provided 303 marked as provided; no hand-written note bioassay (56, 58) provided 304 marked as provided; note: no internal dose in-vivo summary (82, 84, 86–87, 89–93, 95)/in-vivo (82, 84, 86–87, 89–93, 95) provided 305 marked as provided; note: no internal dose in-vivo (63–65)/bioassay (58–59, 61–65, 69) provided 306 note: not monitored notation in file that records show no record of EE receiving dose at INL 307 marked as provided; note: no internal 

exposure 

marked as does not exist; note: no 

recordable dose, see attached letter 

nobi

308 marked as provided; note: internal dose provided in-vivo (61)/bioassay (59–61) provided 309 marked as provided; note: no internal 

exposure 

marked as does not exist; note: no 

recordable dose, see attached letter 

nobi

310 marked as provided; note: no internal 

exposure 

marked as does not exist; note: no 

recordable dose, see attached letter 

nobi

311 marked as provided; note: no internal dose in-vivo (64, 66)/bioassay (62–65) provided 312 marked as provided; note: no internal dose bioassay (54, 56–57, 59–60) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

24 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

313 marked as provided; note: no internal dose in-vivo summary (80)/in-vivo (80) provided 314 marked as provided; note: no internal in-vivo (67)/bioassay (63, 67) provided 315 note: not monitored notation in file that records show no record of EE receiving dose at INL 316 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

317 marked as provided; note: no internal dose bioassay (56, 59–60) provided 318 marked as provided; note: no in-vivo (61, 66)/bioassay (57–63) provided 319 note: not in our systems notation in file that records show no record of EE receiving dose at INL 320 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter in

pr

321 marked as provided; note: no internal dose in-vivo summary (69, 71, 92)/in-vivo (92) provided 322 marked as provided; note: no internal dose bioassay (58–60) provided 323 no notations/markings notation in file that all records are for NRF and no other monitoring at INL 324 marked as provided; note: no internal dose bioassay (56–61) provided 325 marked as provided; note: no internal dose in-vivo (89) provided 326 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

327 marked as provided; note: no internal 

exposure 

note: no recordable dose, see 

attached letter 

nobi

328 marked as provided; note: no internal dose in-vivo (84) provided 329 marked as provided; note: no internal dose in-vivo summary (85–88, 90, 92)/in-vivo (85–88, 90, 92)/bioassay (86–92) provided 330 marked as provided; note: none exist – no bioassays in-vivo (79, 89) provided 331 marked as provided; note: no internal in-vivo (66)/bioassay (62–65, 69) provided 332 marked as provided; note: no internal dose in-vivo (61, 63–66, 68, 70, 74, 81–84, 88)/bioassay (53– 66, 68) provided 333 marked as provided; note: no internal dose note: no recordable dose, see attached letter no

bi

334 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

335 marked as provided; note: no internal dose marked as provided; no hand-written note bi336 marked as provided; note: no monitoring required 337 marked as provided; note: no internal dose bioassay (59–61) provided 338 marked as provided; note: no internal dose in-vivo (88, 90–91, 95) provided 339 note: only ANL dose notation in file that all records are for ANL 340 marked as provided; note: no internal dose in-vivo summary (82, 84–85, 88–95)/in-vivo (82, 84– 85, 88–95) provided 341 marked as provided; note: no internal dose in-vivo summary (82–90, 93–97)/in-vivo (82–90, 93– 95)/bioassay (82–90, 97) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

25 of 49

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

342 note: not monitored notation in file that records show no record of EE receiving dose at INL 343 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter in344 note: not monitored notation in file that records show no record of EE receiving dose at INL 345 marked as provided; note: no internal in-vivo (70, 74, 92)/bioassay (64–66) provided 346 marked as provided; note: no internal dose in-vivo summary (81–85, 87, 89, 91)/in-vivo (82–85, 87, 89, 91)/bioassay (88–98) provided 347 marked as provided; note: no analytical records in-vivo (66, 71, 75, 80–87, 88–91)/bioassay (64–66) provided 348 note: not monitored notation in file that records show no record of EE receiving dose at INL 349 marked as provided; note: no internal dose in-vivo (87–88, 90–93, 95) provided 350 marked as provided; note: no internal records in-vivo (80–82, 91–95) provided 351 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

352 note: not monitored notation in file that records show no record of EE receiving dose at INL 353 marked as provided; note: no internal dose/no recordable dose in-vivo summary (81–95)/in-vivo (81–95)/bioassay (83–96) provided 354 marked as provided; note: no analytical records in-vivo (61)/bioassay (55, 61) provided 355 marked as provided; note: no internal dose in-vivo summary (84–92, 94–95)/in-vivo (84–92, 94– 95) provided 356 marked as provided; note: no internal in-vivo (66–67, 85)/bioassay (60–65) provided 357 note: not monitored notation in file that records show no record of EE receiving dose at INL other than NRF 358 marked as provided; no hand-written note bioassay (57) provided 359 marked as provided; note: no internal dose in-vivo summary (82–90)/in-vivo (82–90) provided 360 note: not monitored notation in file that records show no record of EE receiving dose at INL 361 marked as provided; note: no internal in-vivo (73, 77, 80–81, 83–87, 89–93)/bioassay (63) provided 362 marked as provided; note: no internal note: no recordable dose, see attached letter no

bi

363 marked as provided; note: no internal bioassay (58, 60–61, 67) provided 364 marked as provided; note: no internal in-vivo (62–63, 65–66, 69, 71, 75, 79)/bioassay (56–66) provided 365 marked as provided; note: no internal in-vivo (87–88) provided 366 marked as provided; note: no internal dose in-vivo summary (93–94)/in-vivo (93–94) provided 367 marked as provided; note: no internal in-vivo (66)/bioassay (62–66) provided 368 marked as provided; note: no internal dose in-vivo summary (84–87, 89–97)/in-vivo (84–87, 89– 93, 95) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

26 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 I

369 marked as provided; note: no internal dose in-vivo (62)/bioassay (55–62) provided 370 marked as provided; note: no internal 

exposure 

marked as does not exist; note: no 

recordable dose, see attached letter 

nobi

371 marked as provided; note: no internal in-vivo (65)/bioassay (58, 61–65) provided 372 note: no records found notation in file that records show no record of EE receiving dose at INL 373 marked as provided; note: no internal in-vivo (62–63, 65)/bioassay (56–57, 59–65) provided 374 marked as provided; note: no internal dose in-vivo summary (82, 95)/in-vivo (67, 72, 76, 82, 85) provided 375 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

376 marked as provided; note: no internal dose in-vivo summary (83)/in-vivo (83) provided 377 marked as provided; note: no internal in-vivo (84)/bioassay (60–65) provided 378 marked as provided; note: no internal in-vivo (69–70, 75, 77–80, 82–84)/bioassay (69, 82–83) provided 379 marked as provided; note: no internal in-vivo (87–89, 91–94) provided 380 marked as provided; note: no internal in-vivo (82–85, 87, 90, 92) provided 381 marked as provided; note: no internal dose note: no recordable dose, see attached letter no

bi

382 marked as provided; note: no internal in-vivo (61, 63–67)/bioassay (58–65, 69) provided 383 note: not monitored notation in file that records show no record of EE receiving dose at INL 384 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter in385 marked as provided; note: no internal dose in-vivo (73, 78, 80–81) provided 386 marked as provided; note: no internal in-vivo summary (65, 68–69, 79, 84)/in-vivo (65, 68– 69, 73, 79, 84)/bioassay (53, 55, 60–63, 67) provided 387 marked as provided; note: no internal in-vivo summary (79–80)/in-vivo(79–80)/bioassay (69) provided 388 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

389 note: not monitored notation in file that records show no record of EE receiving dose at INL 390 marked as provided; note: no internal in-vivo (65, 68)/bioassay (59–65) provided 391 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

392 marked as provided; note: no internal in-vivo (66, 68, 72, 77)/bioassay (57–66) provided 393 marked as provided; note: no internal bioassay (57–60) provided 394 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

395 marked as provided; note: no internal dose note: no recordable dose, see attached letter no

bi

396 marked as provided; note: no internal 

exposure 

in-vivo (91) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

27 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

397 note: not monitored notation in file that records show no record of EE receiving dose at INL 398 marked as provided; note: no internal dose in-vivo (80) provided 399 marked as provided; note: no internal dose in-vivo (82–85, 88, 90–91) provided 400 marked as provided; note: no internal dose in-vivo (91) provided 401 marked as provided; note: no internal bioassay (55, 59–61, 64) provided 402 marked as provided; note: no internal in-vivo (68, 72, 74–75, 77, 79–80, 84)/bioassay (53–54, 56–66) provided 403 marked as provided; note: no internal dose in-vivo (82)/bioassay (56–57, 59–60, 62–64) provided 404 marked as provided; note: no internal in-vivo (67)/bioassay (56–63, 65–66) provided 405 marked as provided; note: no recordable dose in-vivo summary (65–66, 74)/in-vivo (61–63, 65–66, 69, 73–74)/biosasay (57–66) provided 406 note: not in system notation in file that records show no record of EE receiving dose at INL 407 marked as provided; note: no internal in-vivo (66, 68, 82, 94, 96) provided 408 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

409 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

410 marked as provided; note: no internal dose marked as does not exist; note: no recordable dose, see attached letter no

bi

411 marked as provided; note: no internal in-vivo (66, 69, 71)/bioassay (58–65) provided 412 marked as provided; note: no internal in-vivo (63–66, 70–71)/bioassay (53–66) provided 413 marked as provided; note: no internal bioassay (61–66) provided 414 marked as provided; note: no internal dose in-vivo (82, 86, 89–90) provided 415 marked as provided; note: no internal bioassay (59–61, 65) provided 416 marked as provided; note: no internal dose note: no recordable dose, see attached letter in417 marked as provided; note: no internal dose in-vivo (91) provided 418 marked as provided; note: no internal dose in-vivo (82, 84–87, 89) provided 419 marked as provided; note: no internal dose note: no recordable dose, see attached letter no

bi

420 marked as provided; note: no internal marked as does not exist; note: no recordable dose, see attached letter no

bi

421 marked as provided; note: no internal in-vivo (64–65, 68, 74)/bioassay (57–59, 61–66) provided 422 marked as provided; note: no internal dose in-vivo summary (82, 86–87, 90)/in-vivo (82, 86–87, 90) provided 423 marked as provided; note: no internal dose in-vivo summary (92)/in-vivo (92) provided 424 marked as provided; note: no internal in-vivo (73) provided 425 note: all dose is NRF in-vivo (81) provided 426 marked as provided; note: no internal in-vivo (65)/bioassay (67) provided 427 marked as provided; note: no internal notation in file stating that all records are for ANL 428 marked as provided; note: no internal in-vivo (75) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

28 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

429 marked as provided; note: no internal dose in-vivo (87–88, 90–91, 94) provided 430 no notation/markings in-vivo (82) provided 431 marked as provided; note: no internal in-vivo (66, 70, 75, 77, 95)/bioassay (64–65) provided 432 marked as provided; note: no internal bioassay (60–61) provided 433 marked as provided; note: no internal in-vivo (66–67, 70–71, 82)/bioassay (64, 67) provided 434 note: not monitored notation in file that records show no record of EE receiving dose at INL 435 marked as provided; note: no internal dose note: not monitored no

bi

436 marked as provided; note: no internal in-vivo (76, 78, 81–89) provided 437 marked as provided; note: no internal bioassay (55, 67) provided 438 marked as provided; note: no internal in-vivo (73, 87–88) provided 439 marked as provided; note: no internal dose note: no internal dose, see attached letter, not monitored no

bi

440 marked as provided; note: no internal dose in-vivo (78–79, 91) provided 441 marked as provided; note: no internal dose in-vivo (69, 73–75, 77, 79, 82–87)/bioassay (82–84, 86) provided 442 marked as provided; note: no internal bioassay (57–61) provided 443 marked as provided; note: no internal dose notation in file stating that all records are for ANL 444 marked as provided; note: no internal dose in-vivo (84)/bioassay (56) provided 445 marked as provided; note: no internal dose marked as does not exist; no hand- written note no

bi

446 marked as provided; note: no internal dose note: no recordable dose, see attached letter, not monitored no

bi

447 marked as provided; note: no internal dose in-vivo (81, 90–95) provided 448 marked as provided; note: no internal dose in-vivo (91) provided 449 marked as provided; note: see attached in-vivo (61, 63, 65–66, 69, 71)/bioassay (56–63, 65–66) provided 450 marked as provided; note: no internal dose note: not monitored no

bi

451 marked as provided; note: no internal dose in-vivo (61–66, 68, 71, 75, 80–86, 88–90, 93)/bioassay (57–66) provided 452 marked as provided; note: no internal dose marked as does not exist; note: not monitored, see attached letter no

bi

453 marked as provided; note: no internal dose in-vivo (91) provided 454 marked as provided; no hand-written note bioassay (59–64) provided 455 marked as provided; note: no internal dose in-vivo (79–81, 83–85, 87, 89–90) provided 456 marked as provided; note: no internal dose in-vivo (66, 70, 82–83, 86–87)/bioassay (59–63, 66) provided 457 marked as provided; note: no internal dose in-vivo (81, 89–90, 92–93) provided 458 marked as provided; note: no internal dose in-vivo (92) provided 459 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

460 marked as provided; no hand-written note in-vivo (65)/bioassay (59, 61–63, 65) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

29 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

461 marked as provided; note: no internal dose note: not monitored no

bi

462 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

463 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

464 marked as provided; note: no internal dose in-vivo (86–87) provided 465 marked as provided; note: no internal dose in-vivo (62–65, 69, 72, 76, 81–82, 84–87)/bioassay (57– 66) provided 466 marked as provided; note: no internal dose marked as does not exist; note: consistent with his employment no

bi

467 note: nothing to report notation in file that all records are ANL-W or NRF 468 marked as provided; note: no internal dose in-vivo (64–66, 69, 73, 77, 95)/bioassay (64–66, 68) provided 469 marked as provided; note: no internal dose in-vivo (73, 75–78) provided 470 marked as provided; note: no internal dose in-vivo (80, 85–86, 88–92, 94–95) provided 471 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

472 marked as provided; note: no internal dose in-vivo (93–94) provided 473 marked as provided; note: no internal dose in-vivo (86) provided 474 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

475 marked as provided; note: no internal in-vivo (70) provided 476 marked as provided; note: no internal dose in-vivo (85–89, 91, 93, 95) provided 477 marked as provided; note: no internal dose bioassay (59–61) provided 478 marked as provided; note: no internal dose in-vivo (82, 93) provided 479 note: not monitored notation in file that records show no record of EE receiving dose at INL 480 marked as provided; note: no recordable internal dose/monitoring not required in-vivo (80–81, 86–87, 90 481 marked as provided; note: no internal dose in-vivo (73, 75)/bioassay (53–56) provided 482 marked as provided; note: no internal dose in-vivo (87–88, 93–94) provided 483 marked as provided; note: no internal dose note: no recordable dose, see attached letter, not monitored no

bi

484 marked as provided; note: no internal dose note: not monitored no

bi

485 

marked as provided; note: no internal dose in-vivo summary (65–66, 79, 81–85, 88–89)/in-vivo 

(63–67, 71, 75, 79, 81–85, 88–89)/bioassay (56–65) provided 

486 marked as provided; note: no internal dose note: no internal dose, see attached letter, not monitored no

bi

487 marked as provided; note: no internal dose note: no internal dose, see attached letter, not monitored no

bi

488 marked as provided; note: no internal dose/no monitoring required 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

30 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

489 marked as provided; note: no internal dose in-vivo (90–94) provided 490 marked as provided; note: no internal dose in-vivo summary (66)/in-vivo (66, 68)/bioassay (66, 69) provided 491 marked as provided; note: no internal dose marked as provided; note: no internal dose, see attached letter in492 marked as provided; note: no internal dose marked as provided; no hand-written note in493 marked as provided; note: no internal dose in-vivo summary (94)/in-vivo (94) provided 494 marked as provided; note: no internal dose in-vivo summary (90)/in-vivo (90)/bioassay (90) provided 495 marked as provided; note: no internal dose note: no internal dose, see attached letter, not monitored no

bi

496 marked as provided; note: no internal dose in-vivo (82, 83) provided 497 marked as provided; note: no internal dose in-vivo summary (65, 85)/in-vivo (85) provided 498 marked as provided; note: no internal dose 499 marked as provided; note: no internal dose marked as provided; note: no recordable dose, see attached letter bi500 marked as provided; note: no internal dose in-vivo summary (97) provided 501 marked as provided; note: no internal dose in-vivo (76, 85) provided 502 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

503 marked as provided; note: no internal dose in-vivo (61, 66)/bioassay (57–66) provided 504 marked as provided; note: no internal 

exposure 

in-vivo (81) provided 

505 marked as provided; note: no internal dose in-vivo (73, 75–77, 79–83, 85–90)/bioassay (56–61) provided 506 marked as provided; note: no internal dose marked as provided; note: no internal dose, see attached letter in

62

507 marked as provided; note: no internal dose note: not monitored no

bi

508 marked as provided; note: no internal dose marked as does not exist; note: not monitored, see attached letter no

bi

509 marked as provided; note: no internal dose marked as provided; no hand-written note bi510 marked as provided; note: no internal dose in-vivo (82) provided 511 marked as provided; note: no internal dose in-vivo (62)/bioassay (57–62) provided 512 marked as provided; note: no internal dose bioassay (58) provided 513 marked as provided; note: no internal dose marked as does not exist; note: see attached letter no

bi

514 note: not monitored notation in file that records show no record of EE receiving dose at INL 515 note: not monitored notation in file that records show no record of EE receiving dose at INL 516 note: not monitored notation in file that records show no record of EE receiving dose at INL 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

31 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

517 marked as provided; note: no internal dose in-vivo summary (66)/in-vivo (66, 69)/bioassay (53–66) provided 518 marked as provided; no hand-written note in-vivo summary (88–98)/in-vivo (88, 90–91, 93– 95)/bioassay (88–97) provided 519 marked as provided; note: no internal dose note: no recordable dose, see attached letter no

bi

520 marked as provided; note: no internal dose note: no recordable dose, see attached letter no

bi

521 marked as provided; note: no internal dose note: no internal dose, see attached letter, not monitored no

bi

522 marked as provided; note: no internal dose in-vivo (93, 95) provided 523 marked as provided; note: no internal dose note: no internal dose, see attached letter, not monitored no

bi

524 marked as provided; no hand-written note in-vivo (67, 69–70, 73–94)/bioassay (81–84, 86) provided 525 marked as provided; note: no internal dose bioassay (59, 61–65) provided 526 note: not monitored notation in file that records show no record of EE receiving dose at INL 527 note: US Navy not reported notation in file that all records are for US Navy which are not reported 528 marked as provided; note: no internal dose bioassay (69) provided 529 marked as provided; note: no internal dose in-vivo (66–67, 71, 77)/bioassay (60–65) provided 530 marked as provided; note: no monitoring required 531 no markings; note: no internal dose marked as provided; no hand-written note in532 no markings; note: no internal dose in-vivo (64, 69, 73–74, 76)/bioassay (53–65) provided 533 marked as provided; note: no recordable dose marked as provided; no hand-written note in534 no markings; note: no internal dose in-vivo (63–65, 69, 71–73, 77–79, 89)/bioassay (56–66) provided 535 note: not monitored notation in file that records show no record of EE receiving dose at INL 536 marked as provided; note: no recordable dose in-vivo (82–83) provided 537 marked as provided; note: no recordable dose in-vivo (71) provided 538 marked as provided; note: no recordable dose bioassay (58) provided 539 marked as provided; note: no recordable dose in-vivo (61, 63, 81–83, 93)/bioassay (57–66, 82–83) provided 540 note: not monitored notation in file that records show no record of EE receiving dose at INL 541 marked as provided; note: no monitoring required 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

32 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

542 marked as provided; note: no recordable dose in-vivo (61–63)/bioassay (56–63) provided 543 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter bi544 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

545 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter in546 marked as provided; note: no recordable dose in-vivo (61, 63–66, 69, 72, 76)/bioassay (53–55, 57–66, 78) provided 547 marked as provided; note: no recordable dose 548 marked as provided; note: included in-vivo (76, 80, 82–83, 85, 88–95)/bioassay (56, 59, 63– 64, 90) provided 549 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter in550 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter in551 marked as provided; note: no recordable dose note: no recordable dose, see attached letter in552 marked as provided; note: no recordable dose in-vivo (64, 68, 70, 77)/bioassay (59–66) provided 553 note: not monitored at INL notation in file that records show no record of EE receiving dose at INL 554 marked as provided; note: no recordable dose marked as does not exist; note: not monitored, see attached letter no

bi

555 marked as provided; note: no recordable dose bioassay (57, 60–65) provided 556 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

557 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

558 note: not monitored at INL notation in file that records show no record of EE receiving dose at INL 559 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter bi560 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

561 marked as provided; note: no recordable dose marked as provided; no hand-written note in

pr

562 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

563 marked as provided; note: no recordable dose marked as provided; no hand-written note in

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

33 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

564 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter bi565 marked as provided; note: no recordable dose note: no recordable dose, see attached letter, not monitored no

bi

566 marked as provided; note: no recordable dose no notations/markings bi567 marked as provided; note: no recordable dose marked as provided; no hand-written note bi568 marked as provided; note: no recordable dose marked as provided; no hand-written note in569 marked as provided; note: no recordable dose note: no internal dose, see attached letter, not monitored no

bi

570 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter in571 marked as provided; note: no recordable dose note: not monitored no

bi

572 marked as provided; note: no recordable dose in-vivo (63, 65, 67, 71, 75, 84–89, 91–93)/bioassay (61– 66) provided 573 marked as provided; note: no recordable dose marked as provided; no hand-written note bi574 marked as provided; note: no recordable dose in-vivo (86) provided 575 marked as provided; note: no recordable dose bioassay (56–60, 62) provided 576 

marked as provided; note: no recordable dose 

marked as provided; no hand-written note 

in95pr

577 marked as provided; note: no recordable dose note: not monitored no

bi

578 marked as provided; note: no recordable dose additional request already sent to INL – response received – in-vivo (78) provided 579 marked as provided; no hand-written note marked as provided; note: see transmittal letter no

bi

580 marked as provided; note: no recordable dose note: no recordable dose, see attached letter in581 marked as provided; note: no recordable dose note: no recordable dose, see attached letter in582 marked as provided; note: no recordable dose in-vivo (81–82, 84–91, 94)/bioassay (81) provided 583 marked as provided; note: no recordable dose bioassay (57–61) provided 584 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter in585 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter in

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

34 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

586 marked as provided; note: no recordable dose bioassay (53–57, 59, 61–64) provided 587 marked as provided; note: no recordable dose in-vivo (68)/bioassay (68) provided 588 marked as provided; note: no recordable dose in-vivo (61, 73, 77)/bioassay (60–61) provided 589 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

590 marked as provided; note: no recordable dose in-vivo (70, 73)/bioassay (66) provided 591 marked as provided; note: no recordable dose in-vivo (80, 82–85)/bioassay (60–61) provided 592 marked as provided; note: no recordable dose marked as provided; no hand-written note in

pr

593 marked as provided; note: no recordable dose marked as provided; no hand-written note in594 marked as provided; note: no recordable dose in-vivo (63–66, 70–71, 81–82)/bioassay (57–66) provided 595 marked as provided; note: no recordable dose note: no recordable dose, see attached letter no

bi

596 marked as provided; note: no recordable dose in-vivo (87)/bioassay (56–60, 63–64) provided 597 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter in598 note: not monitored notation in file that records show no record of EE receiving dose at INL 599 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

600 marked as provided; note: no recordable dose marked as provided; no hand-written note in

62

601 note: not monitored notation in file that records show no record of EE receiving dose at INL 602 marked as provided; note: no recordable dose note: no internal exposure, see attached letter, not monitored no

bi

603 marked as provided; note: no recordable dose marked as provided; note: not normally required, note "training" in604 marked as provided; note: no recordable dose in-vivo (72, 81–82, 90–95) provided 605 marked as provided; note: no recordable dose 606 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

607 marked as provided; note: no recordable dose in-vivo (65–67, 71)/bioassay (53–55, 59–66) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

35 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

608 marked as provided; note: no recordable dose marked as provided; no hand-written note in609 marked as provided; note: no recordable dose bioassay (56–61) provided 610 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter no

bi

611 note: not monitored notation in file that records show no record of EE being monitored or receiving dose at INL 612 marked as provided; note: no recordable dose note: no recordable dose, see attached letter no

bi

613 marked as provided; note: no recordable dose note: no recordable dose, see attached letter no

bi

614 marked as provided; note: no recordable dose in-vivo (65, 69, 73–75, 77, 79, 81)/bioassay (53–65) provided 615 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

616 marked as provided; note: no recordable dose note: no recordable dose, see attached letter bi617 marked as provided; note: no recordable dose bioassay (57–60) provided 618 marked as provided; note: no recordable dose marked as provided; no hand-written note in619 marked as provided; note: no recordable dose bioassay (67) provided 620 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

621 marked as provided; note: no recordable dose no notations/markings in622 marked as provided; note: no recordable dose marked as provided; no hand-written note in623 marked as provided; note: no recordable dose in-vivo (62–67, 72, 76, 81–83, 85–87, 89–91, 95)/bioassay (60–66) provided 624 marked as provided; note: no recordable dose in-vivo (66, 68, 72, 75, 77, 80)/bioassay (61–66) provided 625 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

626 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

627 

marked as provided; note: no recordable dose 

marked as provided; note: no recordable dose, see attached letter 

in95pr

628 marked as provided; note: no recordable dose in-vivo (62)/bioassay (56–58, 61–62) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

36 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

629 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter in630 marked as provided; note: no recordable dose marked as provided; no hand-written note in631 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

632 marked as provided; note: no recordable dose note: no recordable dose, see attached letter no

bi

633 marked as provided; note: no recordable dose bioassay (63–64) provided 634 marked as provided; note: no recordable dose note: no recordable dose, see attached letter no

bi

635 marked as provided; note: no recordable dose in-vivo (65, 68, 72, 75, 77–79, 82)/bioassay (53–66, 81– 82) provided 636 marked as provided; note: no recordable dose note: no recordable dose, see attached letter bi637 

note: not monitored at INL notation in file that records show no record of EE being 

monitored or receiving dose at INL 

638 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

639 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

640 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

641 marked as provided; note: no recordable dose note: no recordable dose, see attached letter, not monitored no

bi

642 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

643 marked as provided; note: no recordable dose in-vivo (66, 70–71, 75, 84)/bioassay (57–66) provided 644 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

645 marked as provided; note: no recordable dose no notations/markings in646 marked as provided; note: no recordable dose bioassay (62–65) provided 647 marked as provided; note: no recordable dose marked as provided; note: no internal dose, see attached letter in648 marked as provided; note: no recordable dose bioassay (59–63, 65) provided 649 marked as provided; note: no recordable dose marked as provided; no hand-written note in

pr

650 page not provided bioassay (68) provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

37 of 49

A B C D 

SC&A Case INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

ID # NOTATION ON OCAS-INT-004 

I

651 

note: not monitored notation in file that records show no record of EE being 

monitored or receiving dose at INL 

652 marked as provided; note: no recordable dose marked as provided; no hand-written note in653 marked as provided; note: no recordable dose marked as does not exist; note: see attached letter no

bi

654 marked as provided; note: no recordable dose marked as provided; no hand-written note in655 marked as provided; note: no recordable dose marked as provided; no hand-written note bi656 marked as provided; note: no recordable dose in-vivo (64, 70, 72)/bioassay (57–58, 61–65) provided 657 marked as provided; note: no recordable dose note: not monitored no

bi

658 marked as provided; note: no recordable dose marked as provided; note: no recordable dose, see attached letter bi659 marked as provided; note: no recordable marked as provided; note: no internal dose, see attached letter in

65

660 marked as provided; note: none recorded note that 1966-73 NRF dose not reported and 1974 not monitored 661 marked as provided; note: no recordable dose in-vivo (83)/bioassay (70) provided 662 marked as provided; note: no recorded dose notation in file that records show no record of EE being monitored or receiving dose at INL 663 marked as provided; note: no recordable dose in-vivo (83–85) provided 664 marked as provided; note: no recordable dose in-vivo summary (65–66, 81–84, 86)/in-vivo (62, 65– 66, 81–84, 86)/bioassay (53–59, 61–65) provided 665 

page not provided marked as provided; note: no 

recordable dose, see attached letter 

in8887

666 marked as provided; no hand-written note marked as provided; note: no recordable dose, see attached letter no

bi

667 marked as provided; note: no recordable dose notation in file that records show no record of EE being monitored or receiving dose at INL 668 marked as provided; note: no recordable dose in-vivo (95) provided 669 marked as provided; note: no recordable dose in-vivo (79–80) provided 670 marked as provided; note: no recordable dose in-vivo (88) provided 671 note: not monitored notation in file that records show no record EE being monitored or receiving dose at INL 672 note: not monitored notation in file that records show no record EE being monitored or receiving dose at INL 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

38 of 49

: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

Ho is report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

NOTICE

wever, th

A B C D 

SC&A Case 

ID #

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 

INITIAL RESPONSE – 

INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT-004 

I

673 marked as provided; note: no recordable dose in-vivo (85–95)/bioassay (86) provided 674 marked as provided; note: no recordable dose in-vivo (84–85, 87, 99–00) provided 675 marked as provided; note: no recordable dose in-vivo (63–64, 66, 70, 76–77)/bioassay (56–66) provided 676 marked as provided; no hand-written note in-vivo (84–89)/bioassay (83–86) 677 marked as provided; note: no recordable dose in-vivo (77) provided 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

39 of 49

APPENDIX B: REVIEW OF ANL-W CASES WITH POC <50% POTENTIA

AFFECTED BY OCAS-PER-017 

A B C D 

SC&A 

Case ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT

004 

1 marked as provided; hand-written note implies other information not readily available in-vivo summary (91–95)/in-vivo (85, 88–89, 91–95) provided 2 marked as provided; no hand-written note in-vivo summary (66–67, 69, 71, 81, 87, 89–91, 93)/in-vivo (63, 66–67, 69–72)/bioassay (60, 62–66) provided 3 marked as provided; note: no recordable dose in-vivo (66–67, 69, 71)/bioassay (59, 62–66) provided 4 marked as provided; note: no analytical records in-vivo summary (66–69, 72, 79–84, 86–89)/in-vivo (75, 77, 79– 84, 86, 88–89) provided 5 no notations/markings response appears to be solely from ANL-E 6 marked as provided; note: no internal dose in-vivo summary (66, 79, 81–90)/in-vivo (65–73)/bioassay (59– 60, 62–66) provided 7 marked as provided; note: no internal dose in-vivo summary (66, 68, 80–84, 86–92)/in-vivo (64–72)/bioassay (62–66, 80–81) provided 8 marked as provided; no hand-written note in-vivo summary (66, 68, 79–97)/bioassay (79, 81, 95) provided 9 marked as provided; note: no recordable dose 

10 marked as provided; note: no internal dose in-vivo summary (68, 71, 73, 76, 79–80, 82–95)/in-vivo (67, 69, 71–73, 76) provided 11 marked as provided; note: no internal dose in-vivo (72) provided 12 no notations/markings in-vivo summary (86, 88–95, 97) provided 13 marked as provided; note: no internal dose in-vivo summary (79–87, 89–92, 94–95) provided 14 marked as provided; note: no internal dose in-vivo summary (66–68, 71)/in-vivo (66–72)/bioassay (59–60, 62–66) provided 15 marked as provided; no hand-written note in-vivo summary (65–66, 68, 71, 79, 82–93, 95)/in-vivo (66–68, 70–72)/bioassay (63, 66) provided 16 marked as provided; note: no internal dose bioassay (79) provided 17 ANL-W response not yet received 18 marked as provided; note: no internal dose in-vivo summary (67–68, 70)/in-vivo (67–72)/bioassay (67) provided 19 marked as does not exist; no hand-written note response appears to be solely from ANL-E marked as provided; note: no internal dose 20 notation stating not monitored notation in file stating that EE did not receive dose at ANL-W (there is bioassay data available for ANL-E) 21 marked as provided; no hand-written note in-vivo summary (67–68, 71, 73, 79–90)/in-vivo (64, 67– 73)/bioassay (59–60, 62–66) provided 22 marked as provided; note: no internal dose in-vivo (71–72)/bioassay (85) provided 23 marked as provided; no hand-written note 24 note: not monitored at ANL notation in file stating dosimetry records show not monitored at ANL-W 25 marked as provided; note: no ANL-W records notation in file stating that only dose information is for INL; no record of ANL-W employment 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

40 of 49

A B C D 

SC&A 

Case ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT

004 

26 marked as provided; note: no internal dose 27 marked as provided; note: no internal exposure 28 marked as provided; note: no analytical records in-vivo (67)/bioassay (67) provided 29 

marked as provided; note: no recordable dose marked as does not exist; note: 

see attached letter 

30 marked as provided; note: no recordable dose notation in file stating dosimetry records show not monitored at ANL-W 31 note: not monitored at ANL notation in file stating dosimetry records show not monitored at ANL-W 32 marked as provided; note: no internal exposure in-vivo summary (81–82, 90, 95) provided 33 marked as provided; note: none recorded response appears to be solely from ANL-E 34 marked as provided; note: no internal dose in-vivo summary (65–66, 76, 79–93)/in-vivo (65–72, 76)/bioassay (60, 62–66, 80, 82–84) provided 35 marked as provided; note: no internal dose in-vivo summary (92, 98) 36 marked as provided; note: no internal dose 37 marked as provided; note: no internal dose in-vivo summary (66, 70, 73)/in-vivo (66, 68–69, 71–73)/bioassay (58–60, 62–66) provided 38 marked as provided; note: no recordable dose in-vivo (65–73, 75–76, 78–94)/bioassay (65) provided 39 marked as provided; note: no internal dose in-vivo summary (66, 68–69, 71–72, 76, 79–81)/in-vivo (66–73, 76)/bioassay (65, 79, 81) provided 40 marked as provided; note: no internal dose in-vivo (65–72)/bioassay (60, 62–66) provided 41 marked as provided; note: no internal dose in-vivo (63, 66, 68–72)/bioassay (60–63, 65) provided 42 marked as provided; note: no internal dose 43 marked as provided; note: no internal dose 44 no notations/markings in-vivo (91–95) provided 45 marked as provided; note: no internal dose in-vivo (66–72)/bioassay (64–66) provided 46 marked as provided; note: no internal dose in-vivo summary (66–68, 71, 82, 90)/in-vivo (63, 66–72)/bioassay (59–60, 62–66, 81–82) provided 47 marked as provided; note: no internal dose in-vivo (71–73)/bioassay (69) provided 48 marked as provided; note: no internal dose in-vivo (65–69, 71–73, 75–77, 79–83, 86–89, 91–92)/bioassay (60, 62–65) provided 49 marked as provided; note: no internal dose 50 marked as provided; note: no internal dose in-vivo (64, 67–71, 73)/bioassay (61–66) provided 51 marked as provided; note: no internal dose in-vivo (75) provided 52 marked as provided; note: no recordable dose additional request sent on 11/15/2006 53 marked as provided; no hand-written note in-vivo (63, 67–72)/bioassay (59–60, 62–64) provided 54 marked as provided; note: no internal dose in-vivo (66, 68, 70–72, 77)/bioassay (63–66) provided 55 marked as provided; note: no internal dose in-vivo summary (79–86, 88–97)/bioassay (83, 88, 91, 93–94, 97) provided 56 marked as provided; no hand-written note in-vivo (63, 66–67, 69–72)/bioassay (58, 60, 62–65, 67) provided 57 marked as provided; note: no internal dose in-vivo (64)/bioassay (62–64) provided 58 marked as provided; note: no recordable dose 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

41 of 49

A B C D 

SC&A 

Case ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT

004 

59 marked as provided; note: no internal dose in-vivo summary (70, 88)/in-vivo (65, 67–69, 71–72, 88)/bioassay (59–60, 62–66) provided 60 marked as provided; note: no internal dose in-vivo summary (66–67, 70, 79–82, 84)/in-vivo (66–69, 71–72, 81–82)/bioassay (62, 65, 81–83) provided 61 marked as provided; note: no internal dose in-vivo summary (70, 72, 74, 79–83, 85–90)/in-vivo (74, 81–83, 85–90) provided 62 marked as provided; note: no internal dose in-vivo (76) provided 63 marked as provided; note: no internal exposure 64 marked as provided; note: no recordable dose in-vivo summary (84–95, 97)/bioassay (93) provided 65 marked as provided; note: no recordable dose in-vivo (72–73, 75–89) provided 66 marked as provided; note: no recordable dose in-vivo (63, 66–73, 75–85)/bioassay (62–65) provided 67 marked as provided; note: no recordable dose in-vivo (75–77, 79–81, 83–85, 87–92) provided 68 marked as provided; note: no recordable dose in-vivo (63, 65–71, 73, 76)/bioassay (62–66) provided 69 marked as provided; note: no recordable dose 70 marked as provided; note: no recordable dose in-vivo (76–78, 80–84) provided 71 marked as provided; note: no recordable dose 72 marked as provided; note: no recordable dose 73 note: not monitored at ANL notation in file stating dosimetry records show not monitored at ANL-W 74 marked as provided; note: no recordable dose in-vivo (64, 67–77, 79–81, 83–92)/bioassay (61–66, 81, 83–84) provided 75 marked as provided; note: no recordable dose 76 marked as provided; no hand-written note in-vivo (65–71, 73, 76–78, 82–84)/bioassay (58, 60, 62–66, 69) provided 77 note: not monitored at ANL notation in file stating dosimetry records show not monitored at ANL-W 78 marked as provided; note: no recordable dose 79 marked as provided; note: no recordable dose 80 marked as provided; note: no recordable dose notation in file stating dosimetry records show not monitored at ANL-W 81 marked as provided; note: no recordable dose 82 

marked as provided; note: no recordable dose marked as does not exist; note: 

see attached letter 

83 marked as provided; note: no recordable dose marked as provided; note: see attached letter 84 

no notations/markings additional request already sent to ANL-W on 5/5/2006 marked as provided; note: no 

recordable dose 

85 note: not monitored notation in file stating dosimetry records show not monitored at ANL-W 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

42 of 49

: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

Ho is report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

A B C D 

NOTICE

wever, th

SC&A 

Case ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON OCAS-INT

004 

86 note: not monitored notation in file stating dosimetry records show not monitored at ANL-W 87 marked as provided; note: no recordable dose in-vivo (83)/bioassay (70) provided 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

43 of 49

APPENDIX C: REVIEW OF ANL-E CASES WITH POC <50% POTENTIA

AFFECTED BY OCAS-PER-017 

A B C D 

SC&A 

ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON 

OCAS-INT-004 

I

1 marked as not readily available; no hand-written notation notation of minimal dose based on bioassay (no records in the response) marked as provided; no hand- written note bi

ex

2 no notations/markings notation in file stating no internal radiation exposure records 3 marked as not readily available; no hand-written notation notation in file stating no bioassay records found 4 no notations/markings notation in file stating data was not available marked as does not exist; no hand-written note no

re

5 marked as provided; no hand-written notation bioassay card and internal rad exposure record provided 6 marked as does not exist; no hand-written notation notation in file stating no bioassay records found 7 marked as does not exist; no hand-written note notation in file stating no internal radiation records; second notation stating no bioassay records found 8 marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure records; second notation stating no bioassay records found 9 

marked as provided; no hand-written note bioassay (internal rad exposure record) provided; later 

response recently received includes bioassay card (not previously provided) 

10 marked as provided; no hand-written notation no internal records/notations in the response marked as does not exist; no hand-written note no

re

11 marked as provided; no hand-written notation bioassay (internal rad exposure record) provided 12 marked as provided; no hand-written notation bioassay (internal rad exposure record) provided 13 marked as does not exist; no hand-written notation notation in file stating no bioassay records found 14 marked as provided; no hand-written notation bioassay card provided 15 marked as provided; no hand-written notation notation in file stating no internal radiation exposure records; bioassay card provided 16 marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure records on file 17 marked as provided; no hand-written notation bioassay card provided 18 marked as provided; no hand-written notation notation in file stating no internal radiation exposure records; bioassay card provided 19 marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure records; second notation stating no bioassay records found 20 marked as provided; no hand-written notation bioassay card provided 21 marked as provided; no hand-written notation bioassay card provided 22 marked as provided; no hand-written notation bioassay card provided 23 marked as provided; no hand-written notation bioassay card and internal rad exposure record provided 24 

marked as provided; no hand-written notation bioassay (internal rad exposure record) provided; second 

response recently received includes bioassay card (not previously provided) 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

44 of 49

A B C D 

SC&A 

ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON 

OCAS-INT-004 

I

25 

marked as provided; no hand-written note bioassay (internal rad exposure record) provided; later 

response recently received includes bioassay card (not previously provided) 

26 marked as provided; no hand-written notation bioassay card provided 27 

marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

28 marked as provided; no hand-written notation bioassay card provided 29 

marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

30 

marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

31 marked as provided; no hand-written notation bioassay card provided 32 marked as provided; note: no internal dose notation in file stating no internal doses assessed marked as provided; no hand- written note bi33 marked as provided; no hand-written notation bioassay (internal rad exposure record) provided 34 marked as provided: note: no internal dose notation in file stating no internal doses assessed marked as provided; no hand- written note bi

ex

35 marked as provided; no hand-written notation bioassay card provided 36 marked as provided: note: no internal dose notation in file stating no internal doses assessed marked as provided; no hand- written note bi

ex

37 marked as provided: note: no internal dose notation in file stating no internal doses assessed marked as provided; no hand- written note bi

ex

38 marked as provided; no hand-written notation bioassay card provided 39 marked as provided: note: no internal dose notation in file stating no internal doses assessed marked as provided; no hand- written note bi40 marked as provided; no hand-written notation bioassay card provided 41 marked as provided; note: none recorded - no records located notation in file stating no internal radiation exposure records; second notation stating no bioassay records found 42 marked as provided; no hand-written note bioassay card provided 43 marked as provided; no hand-written notation bioassay card and internal rad exposure record provided 44 marked as provided; no hand-written notation bioassay card provided 45 marked as provided; no hand-written notation bioassay card provided 46 marked as provided; no hand-written notation bioassay card provided 47 marked as provided; no hand-written notation bioassay card provided 48 

marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

49 

marked as provided; no hand-written notation notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

50 marked as provided; no hand-written note bioassay card and internal rad exposure record provided 

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

45 of 49

: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

Ho is report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Work

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

A B C D 

NOTICE

wever, th

SC&A 

ID # 

INITIAL RESPONSE – 

NOTATION ON OCAS-INT-004 INTERNAL DOSE RECORDS 

ADDITIONAL RESPONSE – 

NOTATION ON 

OCAS-INT-004 

I

51 marked as provided; no hand-written notation bioassay (internal rad exposure record) provided 52 marked as does not exist; no hand-written note notation in file stating no internal radiation exposure records on file 53 marked as provided; no hand-written notation bioassay card provided 54 marked as does not exist; no hand-written notation notation in file stating no internal radiation exposure records on file 55 marked as provided; no hand-written notation bioassay card provided 56 marked as provided; no hand-written notation bioassay card provided 57 marked as provided; no hand-written note bioassay card and internal rad exposure record provided 58 marked as provided; no hand-written notation bioassay card provided 59 

marked as does not exist; no hand-written note notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

60 marked as provided; no hand-written notation bioassay card provided 61 marked as provided; no hand-written notation bioassay card provided 62 marked as does not exist; no hand-written note notation in file stating no internal radiation exposure records on file 63 marked as does not exist; no hand-written note notation in file stating no internal radiation exposure records on file 64 marked as provided; no hand-written note bioassay card provided 65 marked as does not exist; no hand-written note notation in file stating no internal radiation exposure records on file 66 

marked as does not exist; no hand-written note notation in file stating no internal radiation exposure 

records on file; second notation stating no bioassay records found 

67 marked as provided; no hand-written note notation in file stating internal dose fields will be blank if no bioassay samples collected; no internal data in file 68 marked as provided; no hand-written note bioassay (internal rad exposure record) provided 69 marked as does not exist; no hand-written note notation in file stating no bioassay records found 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

46 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

APPENDIX D: INL CASE REWORK STATUS 

SC&A Case ID# Rework Status Comments 

36 Complete 

55 Complete 

58 Complete 

137 Complete 

140 Complete 

151 Complete 

182 Complete 

203 Complete 

237 DR Not Complete PER-017 letter in file 

259 Complete 

266 Complete 

284 Complete 

320 Complete 

335 Complete 

343 DR Not Complete SEC 2010 

384 Complete 

416 Complete 

491 DR Complete No Final DOL Decision 

492 DR Complete No Final DOL Decision 

498 Complete 

499 Complete 

506 Complete 

509 Complete 

531 DR Not Complete 

533 DR Not Complete 

543 Complete 

545 DR Complete No Final DOL Decision 

547 Complete 

549 Complete 

550 Complete 

551 Complete 

559 DR Complete No Final DOL Decision 

563 Complete 

564 DR Complete No Final DOL Decision 

567 DR Complete No Final DOL Decision 

568 DR Not Complete PER-017 letter in file 

570 DR Not Complete PER-017 letter in file 

576 Complete 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

47 of 49

 This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

SC&A Case ID# Rework Status Comments 

NOTICE:

580 DR Not Complete No PER-017 letter in file 

581 Complete 

584 DR Complete No Final DOL Decision 

585 DR Complete No Final DOL Decision 

593 Complete 

597 Complete 

600 Complete 

603 Complete 

605 Complete 

608 DR Not Complete No PER-017 letter in file 

616 DR Not Complete PER-017 letter in file 

621 DR Complete No Final DOL Decision 

627 Complete 

629 Complete 

630 DR Not Complete PER-017 letter in file 

636 DR Complete No Final DOL Decision 

645 Complete 

647 Complete 

649 Complete 

652 DR Not Complete 

654 DR Complete No Final DOL Decision 

655 Complete 

658 DR Not Complete 

659 DR Not Complete 

665 DR Complete No Final DOL Decision 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

48 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

APPENDIX E: ANL-W CASE REWORK STATUS 

SC&A Case ID # Rework Status Comments 

5 Complete 

19 Complete 

26 Complete 

27 DR Complete No Final DOL Decision 

36 DR Complete No Final DOL Decision 

42 DR Not Complete 

49 Complete 

58 DR Not Complete 

63 Complete 

72 Complete 

75 Complete 

78 DR Complete No Final DOL Decision 

79 Complete 

81 DR Complete No Final DOL Decision 

83 Complete 
Effective Date: 

May 15, 2012

Revision No. 

0

Document No. 

SCA-TR-PR2012-0017

Page No. 

49 of 49

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

APPENDIX F: ANL-E CASE REWORK STATUS 

SC&A Case ID # Rework Status Comments 

1 DR Complete No Final DOL Decision 

32 Complete 

34 DR Complete No Final DOL Decision 

36 DR Complete No Final DOL Decision 

37 DR Complete No Final DOL Decision 

39 DR Complete No Final DOL Decision